1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The hyperuricemia therapeutics market is experiencing significant changes, with new therapies and technology integration transforming treatment protocols and market dynamics. Decision-makers face complex choices shaped by evolving clinical practices, patient-centric approaches, supply chain changes, and competitive innovation.
Market Snapshot: Hyperuricemia Therapeutics
The global hyperuricemia therapeutics market is shaped by continuous development in biologics, advancements in digital health, and shifting regional strategies. Senior leaders must consider the impacts of new therapies and regulatory shifts when planning investments or procurement strategies. Growth is influenced by breakthroughs in recombinant uricase therapies, innovative delivery models, and changes in supply chain structures, positioning the market to respond swiftly to adaptation needs and patient access challenges.
Scope & Segmentation
This comprehensive hyperuricemia treatment report provides actionable segmentation across clinical, technical, and distribution dimensions:
- Drug Class: Recombinant uricase, uricosuric agents, xanthine oxidase inhibitors.
- Key Products: Pegloticase, lesinurad, probenecid, allopurinol, febuxostat.
- Route of Administration: Intravenous methods for rapid intervention, oral regimens for chronic care.
- Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies.
- Prescription Types: Branded therapies, generic alternatives.
- Regional Coverage: Americas (includes sub-regions such as United States, Canada, Brazil, Mexico, Argentina), Europe, Middle East & Africa (notable markets like United Kingdom, Germany, France, Italy, Russia, South Africa, and others), Asia-Pacific (featuring China, Japan, India, Australia, South Korea, Indonesia, and more).
- Leading Companies: Teva Pharmaceutical Industries Ltd., Viatris Inc., Novartis AG, AstraZeneca PLC, Horizon Therapeutics plc, Takeda Pharmaceutical Company Limited, Teijin Limited, Zambon S.p.A., Menarini International Operations Luxembourg S.A., Fuji Pharma Co., Ltd.
Key Takeaways for Decision-Makers
- Emerging drug classes and precision medicine are advancing hyperuricemia management, supporting a shift toward more individualized care strategies.
- Integration of digital monitoring tools and telemedicine is enhancing adherence, enabling early intervention and more responsive dose adjustments in real time.
- Tariff implementations, especially those effective January 2025 in the US, are raising operational costs and compelling supply chain evaluation for raw materials in recombinant uricase production.
- Strategic partnerships, co-development, and licensing among major and emerging industry players are redefining competition and accelerating product innovation lifecycles.
- Regional variations in reimbursement models and regulatory frameworks are influencing market entry strategies and product adoption rates, with accessibility differing by geography.
- Segmentation by drug class, administration route, and distribution highlights the need for tailored resource allocation and marketing to meet distinct patient needs.
Tariff Impact: Navigating Cost and Supply Chain Complexity
Senior leaders should closely monitor tariff effects on active pharmaceutical ingredients and finished formulations. The levy of new tariffs in the United States requires manufacturers and distributors to adapt their sourcing, manufacturing, and procurement to maintain continuity of care. This drives investment in alternative manufacturing sites, local sourcing strategies, and risk-diverse acquisition contracts.
Methodology & Data Sources
This report uses a rigorous methodology by blending primary inputs from clinicians, payors, and industry executives with secondary research from clinical trial registries, regulatory filings, and proprietary pharmaceutical databases. Analytical frameworks, including SWOT and PESTEL, validate competitive landscapes and sector drivers. Strict quality control, data triangulation, and validation workshops ensure accuracy and relevance throughout.
Why This Report Matters
- This research equips stakeholders to make evidence-driven decisions, supporting optimized procurement, regulatory navigation, and long-term investment planning.
- Leaders access granular segmentation, actionable insights, and up-to-date trend analysis, strengthening ability to address rapidly changing market and competitive conditions.
- The report’s focus on patient-centric care, tariff strategy, and regional variations aligns with broader changes in healthcare delivery and policy.
Conclusion
Innovation, digital integration, and regional adaptation are redefining standards in hyperuricemia therapeutics. Strategic planning, resilient supply chains, and patient-focused delivery will guide organizations to sustained success amid continued therapy evolution.
This product will be delivered within 1-3 business days.
Table of Contents
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of URAT1 selective inhibitors demonstrating improved renal safety profiles in chronic hyperuricemia management
5.2. Increasing clinical adoption of febuxostat following cardiovascular safety reassessment compared to allopurinol
5.3. Development of pegloticase biosimilars entering late-stage trials to address refractory gout with high uric acid levels
5.4. Integration of pharmacogenomic testing to personalize allopurinol dosing and reduce severe hypersensitivity reactions
5.5. Novel anti-inflammatory adjuncts under investigation to mitigate flare risk during urate-lowering therapy initiation
5.6. Rising collaborations between biotech firms and academic centers to innovate gene editing therapies for urate metabolism alterations
5.7. Regulatory approvals of long-acting uricase formulations improving adherence in patients with refractory hyperuricemia
5.8. Clinical evaluation of fixed-dose combinations of xanthine oxidase and URAT1 inhibitors for enhanced urate lowering efficacy
5.2. Increasing clinical adoption of febuxostat following cardiovascular safety reassessment compared to allopurinol
5.3. Development of pegloticase biosimilars entering late-stage trials to address refractory gout with high uric acid levels
5.4. Integration of pharmacogenomic testing to personalize allopurinol dosing and reduce severe hypersensitivity reactions
5.5. Novel anti-inflammatory adjuncts under investigation to mitigate flare risk during urate-lowering therapy initiation
5.6. Rising collaborations between biotech firms and academic centers to innovate gene editing therapies for urate metabolism alterations
5.7. Regulatory approvals of long-acting uricase formulations improving adherence in patients with refractory hyperuricemia
5.8. Clinical evaluation of fixed-dose combinations of xanthine oxidase and URAT1 inhibitors for enhanced urate lowering efficacy
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
6.2. PESTLE Analysis
8. Drugs for Treating Hyperuricemia Market, by Drug Class
8.1. Introduction
8.2. Recombinant Uricase
8.2.1. Pegloticase
8.3. Uricosuric Agents
8.3.1. Lesinurad
8.3.2. Probenecid
8.4. Xanthine Oxidase Inhibitors
8.4.1. Allopurinol
8.4.2. Febuxostat
8.2. Recombinant Uricase
8.2.1. Pegloticase
8.3. Uricosuric Agents
8.3.1. Lesinurad
8.3.2. Probenecid
8.4. Xanthine Oxidase Inhibitors
8.4.1. Allopurinol
8.4.2. Febuxostat
9. Drugs for Treating Hyperuricemia Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.2. Intravenous
9.3. Oral
10. Drugs for Treating Hyperuricemia Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Drugs for Treating Hyperuricemia Market, by Prescription Type
11.1. Introduction
11.2. Branded
11.3. Generic
11.2. Branded
11.3. Generic
12. Americas Drugs for Treating Hyperuricemia Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Drugs for Treating Hyperuricemia Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Drugs for Treating Hyperuricemia Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Teva Pharmaceutical Industries Ltd.
15.3.2. Viatris Inc.
15.3.3. Novartis AG
15.3.4. AstraZeneca PLC
15.3.5. Horizon Therapeutics plc
15.3.6. Takeda Pharmaceutical Company Limited
15.3.7. Teijin Limited
15.3.8. Zambon S.p.A.
15.3.9. Menarini International Operations Luxembourg S.A.
15.3.10. Fuji Pharma Co., Ltd.
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Teva Pharmaceutical Industries Ltd.
15.3.2. Viatris Inc.
15.3.3. Novartis AG
15.3.4. AstraZeneca PLC
15.3.5. Horizon Therapeutics plc
15.3.6. Takeda Pharmaceutical Company Limited
15.3.7. Teijin Limited
15.3.8. Zambon S.p.A.
15.3.9. Menarini International Operations Luxembourg S.A.
15.3.10. Fuji Pharma Co., Ltd.
List of Figures
FIGURE 1. DRUGS FOR TREATING HYPERURICEMIA MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. DRUGS FOR TREATING HYPERURICEMIA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. DRUGS FOR TREATING HYPERURICEMIA MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. DRUGS FOR TREATING HYPERURICEMIA MARKET: RESEARCHAI
FIGURE 24. DRUGS FOR TREATING HYPERURICEMIA MARKET: RESEARCHSTATISTICS
FIGURE 25. DRUGS FOR TREATING HYPERURICEMIA MARKET: RESEARCHCONTACTS
FIGURE 26. DRUGS FOR TREATING HYPERURICEMIA MARKET: RESEARCHARTICLES
FIGURE 2. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. DRUGS FOR TREATING HYPERURICEMIA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. DRUGS FOR TREATING HYPERURICEMIA MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. DRUGS FOR TREATING HYPERURICEMIA MARKET: RESEARCHAI
FIGURE 24. DRUGS FOR TREATING HYPERURICEMIA MARKET: RESEARCHSTATISTICS
FIGURE 25. DRUGS FOR TREATING HYPERURICEMIA MARKET: RESEARCHCONTACTS
FIGURE 26. DRUGS FOR TREATING HYPERURICEMIA MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. DRUGS FOR TREATING HYPERURICEMIA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PEGLOTICASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PEGLOTICASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY LESINURAD, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY LESINURAD, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PROBENECID, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PROBENECID, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ALLOPURINOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ALLOPURINOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 85. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 86. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 87. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 88. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 89. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 90. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 91. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 94. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 95. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 98. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 99. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 100. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 101. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 102. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 103. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 104. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 105. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 106. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 107. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 112. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 162. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 164. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 171. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 172. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 173. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 174. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 175. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 176. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 177. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 178. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 179. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 184. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 185. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 186. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 187. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 188. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 189. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 190. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 191. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 198. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 199. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 200. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 201. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 202. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 203. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 204. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 205. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 213. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 214. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 215. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 216. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 217. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 218. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 219. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 220. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 221. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 226. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 227. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 228. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 229. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 230. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 231. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 232. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 233. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 234. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 235. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 240. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 256. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 258. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 260. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 262. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 270. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 272. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 274. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 276. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 278. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 282. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 283. DENMARK DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 284. DENMARK DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 285. DENMARK DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 286. DENMARK DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT UR
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PEGLOTICASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PEGLOTICASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY LESINURAD, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY LESINURAD, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PROBENECID, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PROBENECID, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ALLOPURINOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ALLOPURINOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 85. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 86. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 87. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 88. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 89. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 90. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 91. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 94. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 95. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 98. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 99. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 100. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 101. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 102. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 103. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 104. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 105. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 106. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 107. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 112. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 162. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 164. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 171. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 172. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 173. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 174. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 175. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 176. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 177. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 178. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 179. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 184. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 185. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 186. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 187. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 188. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 189. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 190. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 191. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 198. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 199. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 200. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 201. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 202. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 203. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 204. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 205. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 213. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 214. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 215. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 216. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 217. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 218. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 219. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 220. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 221. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 226. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 227. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 228. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 229. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 230. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 231. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 232. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 233. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 234. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 235. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 240. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 256. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 258. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 260. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 262. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 270. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 272. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2025-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2024 (USD MILLION)
TABLE 274. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2025-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 276. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 278. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2024 (USD MILLION)
TABLE 282. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2025-2030 (USD MILLION)
TABLE 283. DENMARK DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 284. DENMARK DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 285. DENMARK DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2024 (USD MILLION)
TABLE 286. DENMARK DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT UR
Samples
LOADING...
Companies Mentioned
The companies profiled in this Drugs for Treating Hyperuricemia market report include:- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Novartis AG
- AstraZeneca PLC
- Horizon Therapeutics plc
- Takeda Pharmaceutical Company Limited
- Teijin Limited
- Zambon S.p.A.
- Menarini International Operations Luxembourg S.A.
- Fuji Pharma Co., Ltd.
